Clinical Trial

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Name: Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control — clinical trial record (NCT07244003)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MESSAGE

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.

Trial Details

NCT Number	NCT07244003
Lead Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions	T2DM (Type 2 Diabetes Mellitus)
Enrollment	430 participants
Start Date	2025-03-29
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-24